Fractional CO Laser for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Clinical, Immunological, and Microbiological Aspects

Overview

Journal Lasers Med Sci

Publisher Springer

Date 2018 Mar 2

PMID 29492713

Citations 24

Authors

Angelamaria Becorpi

Giuseppina Campisciano

Nunzia Zanotta

Zelinda Tredici

Secondo Guaschino

Felice Petraglia

Annalisa Pieralli

Giovanni Sisti

Francesco De Seta

Manola Comar

Affiliations

Soon will be listed here.

Abstract

The composition of vaginal microbiome in menopause and cancer survivor women changes dramatically leading to genitourinary syndrome of menopause (GSM) in up to 70% of patients. Recent reports suggest that laser therapy may be valuable as a not hormonal therapeutic modality. The aim of the present study was to evaluate the effects of fractional CO laser treatment on the vaginal secretory pathway of a large panel of immune mediators, usually implicated in tissue remodeling and inflammation, and on microbiome composition in postmenopausal breast cancer survivors. The Ion Torrent PGM platform and the Luminex Bio-Plex platform were used for microbiome and immune factor analysis. The significant reduction of clinical symptoms and the non-significant changes in vaginal microbiome support the efficacy and safety of laser treatment. Moreover, the high remodeling status in vaginal epithelium is demonstrated by the significant changes in inflammatory and modulatory cytokine patterns. Laser therapy can be used for the treatment of GSM symptoms and does not show any adverse effects. However, further studies will be needed to clarify its long-term efficacy and other effects.

Citing Articles

Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms.

Kershaw V, Jha S Int J Womens Health. 2024; 16:1909-1938.

PMID: 39559516 PMC: 11572048. DOI: 10.2147/IJWH.S446903.

Effect of Vaginal Laser and Topical Therapies on Vulvovaginal Atrophy Symptoms in Breast Cancer Patients: A Systematic Review and Meta-Analysis.

Loczi L, Vlesko G, Elias M, Turan C, Kajtar P, Toth R J Clin Med. 2024; 13(20).

PMID: 39458081 PMC: 11508551. DOI: 10.3390/jcm13206131.

Understanding the Benefits of CO Laser Treatment for Vulvovaginal Atrophy.

Jankovic S, Rovcanin M, Tomic A, Jurisic A, Milovanovic Z, Zamurovic M Medicina (Kaunas). 2024; 60(7).

PMID: 39064488 PMC: 11279000. DOI: 10.3390/medicina60071059.

Treatment of Refractory Vesicourethral Anastomosis Pain Following Radical Prostatectomy Using a Combination of Non-ablative Erbium:YAG and Neodymium:YAG Laser Therapy: A Case Report.

Okui N Cureus. 2024; 16(6):e63036.

PMID: 39050360 PMC: 11268395. DOI: 10.7759/cureus.63036.

Fractional CO Laser, Radiofrequency and Topical Estrogen for Treating Genitourinary Syndrome of Menopause: A Pilot Study Evaluating the Vulvar Vestibule.

Leonor Pereira Campos M, Bianchi-Ferraro A, de Oliveira C, Caceres Nogueira M, Sartori M, Fusco I Medicina (Kaunas). 2024; 60(1).

PMID: 38256341 PMC: 10818998. DOI: 10.3390/medicina60010080.

References

Jih M, Kimyai-Asadi A . Fractional photothermolysis: a review and update. Semin Cutan Med Surg. 2008; 27(1):63-71. DOI: 10.1016/j.sder.2008.01.002. View

Murina F, Karram M, Salvatore S, Felice R . Fractional CO Laser Treatment of the Vestibule for Patients with Vestibulodynia and Genitourinary Syndrome of Menopause: A Pilot Study. J Sex Med. 2016; 13(12):1915-1917. DOI: 10.1016/j.jsxm.2016.10.006. View

Prignano F, Campolmi P, Bonan P, Ricceri F, Cannarozzo G, Troiano M . Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther. 2009; 22 Suppl 1:S8-15. DOI: 10.1111/j.1529-8019.2009.01265.x. View

Arunkalaivanan A, Kaur H, Onuma O . Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017; 28(5):681-685. DOI: 10.1007/s00192-017-3282-y. View

Muhleisen A, Herbst-Kralovetz M . Menopause and the vaginal microbiome. Maturitas. 2016; 91:42-50. DOI: 10.1016/j.maturitas.2016.05.015. View

Sokol E, Karram M . An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause. 2016; 23(10):1102-7. DOI: 10.1097/GME.0000000000000700. View

Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S . Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2014; 30(1):429-36. DOI: 10.1007/s10103-014-1677-2. View

Tierney E, William Hanke C . Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol. 2009; 8(8):723-31. View

Crandall C, Petersen L, Ganz P, Greendale G . Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004; 11(5):519-30. DOI: 10.1097/01.gme.0000117061.40493.ab. View

10.

Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas M . The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric. 2016; 19(5):512-8. DOI: 10.1080/13697137.2016.1212006. View

11.

Shen J, Song N, Williams C, Brown C, Yan Z, Xu C . Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep. 2016; 6:24380. PMC: 4840317. DOI: 10.1038/srep24380. View

12.

Lester J, Pahouja G, Andersen B, Lustberg M . Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015; 5(2):50-66. PMC: 4493485. DOI: 10.3390/jpm5020050. View

13.

Zanotta N, Tornesello M, Annunziata C, Stellato G, Buonaguro F, Comar M . Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation. PLoS One. 2016; 11(3):e0151851. PMC: 4798492. DOI: 10.1371/journal.pone.0151851. View

14.

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B . Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016; 215(6):704-711. DOI: 10.1016/j.ajog.2016.07.045. View

15.

Salvatore S, Leone Roberti Maggiore U, Athanasiou S, Origoni M, Candiani M, Calligaro A . Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015; 22(8):845-9. DOI: 10.1097/GME.0000000000000401. View

16.

Nappi R, Kokot-Kierepa M . Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010; 67(3):233-8. DOI: 10.1016/j.maturitas.2010.08.001. View

17.

Donders G, Bosmans E, Dekeersmaecker A, Vereecken A, Van Bulck B, Spitz B . Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol. 2000; 182(4):872-8. DOI: 10.1016/s0002-9378(00)70338-3. View

18.

Pieralli A, Fallani M, Becorpi A, Bianchi C, Corioni S, Longinotti M . Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016; 294(4):841-6. DOI: 10.1007/s00404-016-4118-6. View

19.

Gaspar A, Brandi H, Gomez V, Luque D . Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2016; 49(2):160-168. PMC: 5347840. DOI: 10.1002/lsm.22569. View

20.

Petricevic L, Unger F, Viernstein H, Kiss H . Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2008; 141(1):54-7. DOI: 10.1016/j.ejogrb.2008.06.003. View